Bromopyruvic acid (3-BP)

Catalog No.S5426 Batch:S542601

Technical Data

Formula	C₃H₃BrO₃
Molecular Weight	166.96	CAS No.	1113-59-3
Solubility (25°C)*	In vitro	DMSO	33 mg/mL (197.65 mM)


* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description	Bromopyruvic acid (3-BP) is a hexokinase II inhibitor with Ki of 2.4 mM for glycolysis/hexokinase inhibition. It is inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs.
In vitro	Bromopyruvic acid, a glycolysis inhibitor, maintains haploidy to a certain extent in both OdG and EG1 haESCs, with no effect on the proliferation or pluripotency of the haESCs.^[2]
In vivo	Bromopyruvic acid reduces the growth of RKO cells with CD36 knockdown at a significantly slower rate in xenograft model.^[3]

Protocol (from reference)

Cell Assay:^{^[2]}	Cell lines Mouse haESC lines AGH-OG-3 and AGH-EG-1 Concentrations 12.5 μg/mL Incubation Time 12 days Method Mouse haESC lines AGH-OG-3 and AGH-EG-1 were cultured in M2iL mediums, which containing knockout DMEM, 15% fetal bovine serum, 1% GlutaMAX, 1% nonessential amino acids, 100 μM β-mercaptoethanol, 100 U Leukemia inhibitory factor, 3 μM CHIR99021, and 1 μM PD0325901. The cells are cultured at 37 ℃ with 5% CO₂ in a humidified environment. 1,25-(OH)₂D3 and 3-BrPA are used at a final concentration of 12.5 μg/mL and 5μM, respectively.
Animal Study:^{^[3]}	Animal Models 4-week-old nude mice injected with RKO cells Dosages 5 mg/kg/day Administration i.p.

Cell Assay:^{^[2]}

Cell lines
Mouse haESC lines AGH-OG-3 and AGH-EG-1
Concentrations
12.5 μg/mL
Incubation Time
12 days
Method
Mouse haESC lines AGH-OG-3 and AGH-EG-1 were cultured in M2iL mediums, which containing knockout DMEM, 15% fetal bovine serum, 1% GlutaMAX, 1% nonessential amino acids, 100 μM β-mercaptoethanol, 100 U Leukemia inhibitory factor, 3 μM CHIR99021, and 1 μM PD0325901. The cells are cultured at 37 ℃ with 5% CO₂ in a humidified environment. 1,25-(OH)₂D3 and 3-BrPA are used at a final concentration of 12.5 μg/mL and 5μM, respectively.

Animal Study:^{^[3]}

Animal Models
4-week-old nude mice injected with RKO cells
Dosages
5 mg/kg/day
Administration
i.p.

References

Selleck's Bromopyruvic acid (3-BP) has been cited by 13 publications

GL-V9 inhibits the activation of AR-AKT-HK2 signaling networks and induces prostate cancer cell apoptosis through mitochondria-mediated mechanism [ iScience, 2024, 27(3):109246]	PubMed: 38439974
METTL14 modulates glycolysis to inhibit colorectal tumorigenesis in p53-wild-type cells [ EMBO Rep, 2023, e56325.]	PubMed: 36794620
3-Bromopyruvate overcomes cetuximab resistance in human colorectal cancer cells by inducing autophagy-dependent ferroptosis [ Cancer Gene Ther, 2023, 10.1038/s41417-023-00648-5]	PubMed: 37558749
ASPP2 suppresses tumour growth and stemness characteristics in HCC by inhibiting Warburg effect via WNT/β-catenin/HK2 axis [ J Cell Mol Med, 2023, 27(5):659-671]	PubMed: 36752127
Microglial hexokinase 2 deficiency increases ATP generation through lipid metabolism leading to β-amyloid clearance [ Nat Metab, 2022, 4(10):1287-1305]	PubMed: 36203054
Integration of glucose and cardiolipin anabolism confers radiation resistance of HCC [ Hepatology, 2022, 75(6):1386-1401]	PubMed: 34580888
Inhibition of abnormally activated HIF-1α-GLUT1/3-glycolysis pathway enhances the sensitivity of hepatocellular carcinoma to 5-caffeoylquinic acid and its derivatives [ Eur J Pharmacol, 2022, S0014-2999(22)00105-4]	PubMed: 35189090
Viral growth factor- and STAT3 signaling-dependent elevation of the TCA cycle intermediate levels during vaccinia virus infection [ PLoS Pathog, 2021, 17(2):e1009303]	PubMed: 33529218
Enhancing cancer-associated fibroblast fatty acid catabolism within a metabolically challenging tumor microenvironment drives colon cancer peritoneal metastasis [ Mol Oncol, 2021, 10.1002/1878-0261.12917]	PubMed: 33528867
A Genetic Screen Identifies Etl4-Deficiency Capable of Stabilizing the Haploidy in Embryonic Stem Cells [ Stem Cell Reports, 2021, 16(1):29-38]	PubMed: 33440180

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.